

American Society of Clinical Oncology

PRESIDENT

Daniel F. Hayes, MD, FACP, FASCO

IMMEDIATE PAST PRESIDENT

Julie M. Vose, MD, MBA, FASCO

PRESIDENT-ELECT

Bruce E. Johnson, MD, FASCO

TREASURER

Craig R. Nichols, MD, FACP

DIRECTORS

Peter C. Adamson, MD

Charles D. Blanke, MD, FACP, FASCO

Linda D. Bosserman, MD, FACP

Walter J. Curran, Jr., MD, FACR

Stephen B. Edge, MD, FACS, FASCO

Paulo M. G. Hoff, MD, PhD, FACP

Arti Hurria, MD

Maha H. A. Hussain, MD, FACP, FASCO

David Khayat, MD, PhD, FASCO

Neal J. Meropol, MD, FASCO

Therese M. Mulvey, MD, FASCO

J. Chris Nunnink, MD, FASCO

Jaap Verweij, MD, PhD

Jedd D. Wolchok, MD, PhD

EX-OFFICIO MEMBERS

Clifford A. Hudis, MD, FACP, FASCO ASCO Chief Executive Officer

Thomas G. Roberts, Jr., MD Chair, Conquer Cancer Foundation Board of Directors November 28, 2016

The Honorable Mitch McConnell Majority Leader United States Senate Washington, DC 20510

The Honorable Paul Ryan Speaker United States House of Representatives Washington, DC 20515 The Honorable Harry Reid Minority Leader United States Senate Washington, DC 20510

The Honorable Nancy Pelosi Minority Leader United States House of Representatives Washington, DC 20515

RE: 21st Century Cures Act

Dear Majority Leader McConnell, Minority Leader Reid, Speaker Ryan, and Minority Leader Pelosi:

The American Society of Clinical Oncology (ASCO) strongly supports the 21st Century Cures Act and encourages a "yes" vote on this important legislation when it is considered by the House and Senate this session. We applaud the House Energy and Commerce and Senate Health, Education, Labor, and Pensions Committees in their bipartisan work on this pivotal legislation. It is more important than ever to realize the potential that big data and precision medicine have to offer in new treatments to patients, and this legislation will help in that effort.

Many provisions in this legislation will help move toward rapid development and dissemination of these important advances. As the professional society representing more than 41,000 members treating patients with cancer, ASCO asks that you see this commitment through to final passage.

We strongly support the 21st Century Cures Act, because of the following provisions;

- Increasing interoperability of Electronic Health Records and preventing the practice of intentional information blocking.
- Providing much needed supplemental funding for the National Institutes of Health and the Food and Drug Administration.
- Requiring transparency for expanded access programs.
- Requiring use of centralized Institutional Review Boards when appropriate.
- Encouraging data standardization, such as requirements for ClinicalTrials.gov.

2318 Mill Road, Suite 800 Alexandria, VA 22314 T: 571-483-1300 F: 571-366-9530 www.asco.org

- Refining Sunshine Act provisions to ensure necessary access by physicians to Continuing Medical Education and peer-reviewed literature.
- Allowing for patient-focused drug development.
- Clarifying the definition of a "clinician-led clinical data registry."
- Providing funding to address the nation's opioid crisis.

We commend the House and Senate for its leadership and bipartisan work over the past 2 years that has led to this significant legislation. We look forward to working to ensure the enactment of *the 21*st *Century Cures* legislation and to working with appropriators in the future to ensure the additional funds authorized in this legislation go towards vital projects, such as jumpstarting the Cancer Moonshot Initiative at the National Cancer Institute. If you have any questions or would like more information, please do not hesitate to contact Amanda Schwartz at (571) 483-1647 or Amanda.Schwartz@asco.org.

Sincerely,

Daniel F. Hayes, MD, FACP, FASCO

President, American Society of Clinical Oncology

Cc: All Members of the United States Congress